U.S. Food and Staples Retail Stock News

Wondering if Dycom Industries at US$510.00 is still reasonably priced after a strong run, or if you might be turning up late to the story. The stock has returned 24.0% over the last week, 17.6% over the last month, 46.7% year to date and 121.8% over the past year, with a very large gain over five years. Recent coverage has focused on Dycom Industries as a contractor involved in communications and infrastructure build outs. This puts the stock on the radar whenever investors focus on network...

Dynagas LNG Partners (DLNG) opened Q1 2026 with total revenue of US$39.9 million and basic EPS of US$0.48, against a trailing twelve month EPS of US$1.49 on US$157.5 million of revenue and earnings growth of 34.3% over the past year. Over recent quarters the partnership has seen revenue move in a relatively tight band between US$38.6 million and US$41.7 million per quarter, while quarterly EPS has ranged from US$0.03 to just above US$0.51. This has fed into a trailing net margin of 34.5%,...

Coursera (NYSE:COUR) has announced a $500 million share repurchase program. The buyback authorizes the company to repurchase its common stock over time, subject to market conditions and other factors. The decision comes as the stock most recently closed at $5.39. For investors watching NYSE:COUR, the buyback plan comes after a difficult stretch for the stock. Coursera shares are down 23.9% year to date and 39.1% over the past year, with a 59.1% decline over three years and 86.4% over five...

If you are wondering whether Capri Holdings trades at a fair price or offers value, it helps to start with how the market has treated the stock recently and what that says about expectations. The share price closed at US$18.51, with a 0.2% gain over the last week, a decline of 5.7% over the last month, a decline of 24.1% year to date, a 2.2% gain over the last year, a decline of 48.7% over three years, and a decline of 65.6% over five years. Recent coverage around Capri Holdings has focused...

Kyndryl Holdings (NYSE:KD) has expanded its collaboration with Broadridge Financial Solutions. The partnership focuses on modernizing and securing core financial platforms with AI-enabled and quantum-safe capabilities. Kyndryl will apply its Kyndryl Bridge and Agentic AI Framework to Broadridge’s critical financial infrastructure. This new agreement puts Kyndryl directly in the middle of core technology upgrades for a large, highly regulated financial services operator. For investors...

Maximus (NYSE:MMS) amended its credit agreement to add $325 million to its existing term B loans. The company plans to use the new debt for share repurchases, working capital, and repayment of existing debt. Maximus, trading at $61.93, is taking on additional term B loan financing that directly affects how it allocates capital between shareholders and creditors. The move comes after the stock declined 28.4% year to date and 13.1% over the past year, with a 22.0% decline over three years and...

Wondering if VICI Properties at US$28.22 is a bargain or a trap? This article walks through what the current price might be implying about the stock's value. The share price is roughly flat year to date with a 0.2% gain, but has declined 1% over the last week and 1.3% over the past month, while the return over the last year is down 5.5%. Recent headlines around VICI Properties have focused on how the stock has trailed the broader Specialized REITs peer group over the last year, reinforcing...

HomesToLife (HTLM) has opened 2026 with Q1 revenue of US$92.5 million and basic EPS of US$0.04. Trailing twelve month revenue sits at US$390.9 million and EPS at US$0.19, framing a business that is currently earning at a higher run rate than any single recent quarter. The company has seen revenue move from US$335.1 million and EPS of US$0.09 on a trailing basis in Q4 2024 to US$390.9 million and EPS of US$0.19 by Q1 2026. This has occurred alongside a trailing net profit margin of 4.5% and...

World Health Organization recommends Regeneron’s maftivimab for priority evaluation in clinical trials for the current Bundibugyo ebolavirus outbreak. Maftivimab is a component of Inmazeb, which is already approved for Zaire ebolavirus treatment. The recommendation positions Regeneron Pharmaceuticals (NasdaqGS:REGN) within an active emergency response affecting multiple African countries. Regeneron Pharmaceuticals, traded as NasdaqGS:REGN, is widely known for its antibody platforms and...

In late May 2026, Safe Pro Group Inc. announced progress in its AI-powered threat detection collaboration with Lantronix, integrating Safe Pro’s algorithms into Lantronix’s Open-Q System-on-Module platform for real-time edge processing across drones and autonomous systems. This work, already tied to Qualcomm-based platforms and U.S. Army Short Range Reconnaissance drones under a Master Services Agreement, underscores Lantronix’s role in enabling NDAA-compliant, on-device AI for defense and...

QTREX Quantum Ltd., formerly Inspira Technologies Oxy B.H.N. Ltd., recently agreed to a US$10,000,000 private placement of 6,666,667 ordinary shares and earlier announced a US$580,000 commercial purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems. Together with the upcoming ticker change to “QTEX” on the Nasdaq Capital Market, these moves highlight fresh institutional interest and early clinical adoption of the ART100 platform by a...

Securities class action lawsuit filed against Zoetis (NYSE:ZTS) and certain executives alleging misleading statements about product safety and demand in the Companion Animal division. Claims focus on disclosures around veterinarian adoption, competitive pressures, and demand trends for key Companion Animal products. The suit alleges that weakening prescriptions, new competition, and slowing demand were not fully communicated before guidance cuts. Zoetis, trading at $77.69, is facing this...

FDA has granted Priority Review for BridgeBio Pharma's BBP-418 for limb-girdle muscular dystrophy type 2I/R9. If approved, BBP-418 could become the first and only therapy for LGMD2I/R9 and the first treatment for any form of LGMD. The Priority Review follows acceptance of BridgeBio's NDA and is tied to plans for a near-term commercial launch. For investors following BridgeBio Pharma (NasdaqGS:BBIO), this regulatory step sits alongside a share price of $66.26, a 3-year return of around 4x,...

Humacyte recently reported research from its acellular tissue engineered vessel (ATEV) program showing long-term structural integrity and self-repair after years of repeated dialysis cannulation, alongside reduced infection susceptibility versus ePTFE grafts, and confirmed that top-line Phase 3 V012 dialysis access results are scheduled for release on June 11, 2026. Together with ongoing late-stage trials and an approved vascular trauma indication, the ATEV’s self-repair profile highlights...

Buckle (BKE) opened Q1 2027 with revenue of US$288.7 million and basic EPS of US$0.93, setting the tone against a trailing twelve month backdrop of US$1.3 billion in revenue and basic EPS of US$4.40. Over the past year, the company has seen quarterly revenue move from US$272.1 million in Q1 2026 to US$399.1 million in Q4 2026 before landing at US$288.7 million in the latest quarter, while basic EPS ranged from US$0.70 to US$1.60 over the same stretch, giving investors a clear read on how top...

Permian Basin Royalty Trust recently declared a reduced cash distribution of US$0.020355 per unit, payable on June 12, 2026, to unitholders of record on May 29, 2026. This lower payout highlights how shifts in royalty income can quickly affect income expectations for investors relying on the trust’s regular distributions. We’ll now examine how the reduced cash distribution shapes Permian Basin Royalty Trust’s investment narrative and what it may mean for income-focused holders. AI is about...

Willis Towers Watson (NasdaqGS:WTW) has announced new leadership appointments in its FINEX North America business to sharpen its cyber strategy. The moves include a new Head of Cyber and roles focused on executing cyber plans and deepening client engagement across North America. The changes come as AI driven risk, governance concerns, and cyber threats draw increased attention across the insurance and risk advisory sector. For investors following NasdaqGS:WTW, these appointments sit at the...

Earlier in May 2026, Netskope announced an integration between its Netskope One AI Security platform and Anthropic’s Claude Compliance API, enabling enterprises to apply unified visibility, policy enforcement, data protection, and compliance controls across their Claude Enterprise deployments in real time. This integration highlights how closely cloud security vendors and AI platform providers are now working together to embed governance directly into everyday AI workflows, reducing manual...

SentinelOne (S) just posted its Q1 2027 numbers, reporting revenue of US$276.7 million, a loss of US$76.2 million on a net income basis, and basic EPS of US$0.23 loss, with trailing twelve month revenue at about US$1.0 billion and a TTM net loss of US$318.7 million or EPS of US$0.96 loss. Over recent quarters the company has seen revenue move from US$229.0 million in Q1 2026 through US$271.2 million in Q4 2026 to US$276.7 million in Q1 2027. Quarterly basic EPS has ranged from a loss of...

Wondering whether Marriott International at around US$375.60 is still reasonable value after a strong run, or if you might be paying too much for the stock. The share price sits at US$375.60 after returns of 1.7% over the past week, 6.1% over the past month, 19.8% year to date and 43.6% over the last year. These moves naturally raise questions about growth potential and changing risk perceptions. Recent news coverage has focused on Marriott International's position as a large global hotel...

UiPath (PATH) has reported Q1 2027 revenue of US$418.4 million and basic EPS of US$0.04, setting a clear marker for how the automation specialist is currently converting top line into profit. The company has seen quarterly revenue move from US$356.6 million in Q1 2026 to US$418.4 million in Q1 2027, while basic EPS shifted from a loss of US$0.04 to a profit of US$0.04. This points to a materially different earnings profile compared with the same period last year. For investors, the key...

HealthEquity’s Q1 2027 earnings snapshot HealthEquity (HQY) opened its Q1 2027 report with total revenue of US$354.6 million and basic EPS of US$0.82, supported by net income of US$69.4 million. Over the past six quarters, revenue has moved from US$311.8 million in Q4 2025 to US$354.6 million in Q1 2027, while quarterly basic EPS has ranged from US$0.30 to US$0.82, and trailing twelve month EPS has reached US$2.70 on revenue of about US$1.3 billion. With trailing net profit margins reported...

If you are wondering whether Kennametal at around US$32.80 still offers value, the starting point is understanding what the current price already implies about the business. The stock is up 13.1% year to date and 56.7% over the past year, even though it has fallen 9.1% in the last week and 14.9% over the past month. This can change how investors view both its potential and its risks. Recent coverage has focused on how Kennametal fits into broader themes in capital goods and industrial...

In late May 2026, Robinhood Markets launched “Agentic Trading” and an “Agentic Credit Card,” letting customers connect third‑party AI agents to dedicated brokerage and virtual card accounts that can autonomously trade equities and make purchases within user‑defined limits and guardrails. The move effectively brings institutional‑style automated tools, such as portfolio construction, rebalancing and rule‑based strategies via platforms like ChatGPT and Claude, directly to retail investors,...